Equities Analysts Offer Predictions for XENE FY2025 Earnings

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Leerink Partnrs decreased their FY2025 earnings per share estimates for shares of Xenon Pharmaceuticals in a report released on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now expects that the biopharmaceutical company will post earnings per share of ($3.80) for the year, down from their previous estimate of ($2.85). The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.13) per share. Leerink Partnrs also issued estimates for Xenon Pharmaceuticals’ FY2026 earnings at ($5.00) EPS, FY2027 earnings at ($3.15) EPS and FY2028 earnings at ($2.45) EPS.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.01. During the same quarter in the previous year, the company posted ($0.73) EPS.

Several other research firms have also recently weighed in on XENE. HC Wainwright reissued a “buy” rating and set a $53.00 price target on shares of Xenon Pharmaceuticals in a report on Thursday, December 12th. Needham & Company LLC reissued a “buy” rating and issued a $60.00 target price on shares of Xenon Pharmaceuticals in a research report on Wednesday, November 13th. Finally, Raymond James reaffirmed an “outperform” rating and set a $50.00 target price on shares of Xenon Pharmaceuticals in a report on Thursday, October 10th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $56.00.

Xenon Pharmaceuticals Stock Performance

Shares of XENE stock opened at $40.45 on Friday. Xenon Pharmaceuticals has a 12-month low of $35.53 and a 12-month high of $50.99. The firm’s 50 day moving average is $40.27 and its 200 day moving average is $40.79.

Insider Activity

In other news, Director Gary Patou sold 4,891 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $41.08, for a total transaction of $200,922.28. Following the sale, the director now owns 23,573 shares in the company, valued at $968,378.84. This trade represents a 17.18 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Sherry Aulin sold 18,709 shares of the company’s stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $41.21, for a total transaction of $770,997.89. The disclosure for this sale can be found here. Insiders have sold 62,383 shares of company stock worth $2,535,891 in the last three months. Company insiders own 5.52% of the company’s stock.

Institutional Investors Weigh In On Xenon Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the company. Blue Trust Inc. grew its stake in shares of Xenon Pharmaceuticals by 174.7% in the 3rd quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 641 shares in the last quarter. Avior Wealth Management LLC purchased a new position in Xenon Pharmaceuticals in the fourth quarter worth about $101,000. nVerses Capital LLC bought a new stake in Xenon Pharmaceuticals during the third quarter worth approximately $102,000. Mirae Asset Global Investments Co. Ltd. raised its position in Xenon Pharmaceuticals by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company’s stock valued at $106,000 after purchasing an additional 487 shares during the period. Finally, KBC Group NV raised its position in Xenon Pharmaceuticals by 39.8% during the fourth quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 780 shares during the period. 95.45% of the stock is currently owned by hedge funds and other institutional investors.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.